Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Legal Officer | September 01, 2026 | September 03, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Adm, Leg & BD Off | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-09-01 | Direct | 7,405 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 7,405 · Balance 7,405 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,837 |
Ending reported balance
After 2021-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-24 · Tax withholding · Disposed 2,416 · Balance 33,865 Row 2 · 2021-02-25 · Sale · Disposed 646 · Balance 33,219 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-02-25 · Sale · Disposed 1,348 · Balance 31,871 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Row 4 · 2021-02-25 · Sale · Disposed 680 · Balance 31,191 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Row 5 · 2021-02-25 · Sale · Disposed 354 · Balance 30,837 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $292.76 | $58,552.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,038 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.46 to $293.05). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $290.65 | $29,065.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,238 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $288.57 | $57,714.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,338 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.57 (range $288.14 to $288.99). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $286.57 | $28,657.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,538 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 225 | $285.67 | $64,275.75 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,638 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $285.67 (range $285.57 to $285.77). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $284.28 | $28,428.00 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,863 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-20-042488 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9 | $288.23 | $2,594.07 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 12 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $288.23 (range $287.96 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18 | $287.50 | $5,175.00 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 11 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,847 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $287.50 (range $286.96 to $287.88). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9 | $286.27 | $2,576.43 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 10 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,865 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $286.27 (range $285.70 to $286.68). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4 | $285.19 | $1,140.76 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,874 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $285.19 (range $284.70 to $285.63). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3 | $284.03 | $852.09 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,878 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $284.03 (range $283.56 to $284.37). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4 | $283.03 | $1,132.12 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,881 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $283.03 (range $282.45 to $283.31). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4 | $282.02 | $1,128.08 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,885 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $282.02 (range $281.42 to $282.38). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11 | $280.34 | $3,083.74 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,889 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $280.34 (range $279.74 to $280.73). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1 | $278.69 | $278.69 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2 | $276.46 | $552.92 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,901 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $276.46 (range $276.44 to $276.49). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2 | $275.54 | $551.08 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,903 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $275.54 (range $275.25 to $275.83). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1 | $273.91 | $273.91 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,905 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,304 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,338 Underlying: Common Stock · 1,304 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,304 | $286.00 | $372,944.00 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,304 | $187.53 | $244,539.12 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,222 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · derivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,561 Underlying: Common Stock · 1,222 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 70 | $274.73 | $19,231.10 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 420 | $273.96 | $115,063.20 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,908 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $273.96 (range $273.68 to $274.31). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 319 | $273.00 | $87,087.00 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,328 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $273.00 (range $272.66 to $273.44). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 140 | $271.64 | $38,029.60 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,647 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $271.64 (range $271.55 to $271.73). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 273 | $270.16 | $73,753.68 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,787 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $270.16 (range $269.77 to $270.75). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,222 | $155.57 | $190,106.54 |
DisclosureSEC source: 0001209191-20-027894 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · derivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,990 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 181 | $264.82 | $47,932.42 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $264.82 (range $264.77 to $264.89). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 554 | $262.48 | $145,413.92 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,019 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $262.48 (range $261.98 to $262.94). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 195 | $261.21 | $50,935.95 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,573 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $261.21 (range $260.88 to $261.56). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $260.16 | $182,112.00 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,768 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $260.16 (range $259.74 to $260.64). Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $259.19 | $181,433.00 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,468 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $259.19 (range $258.74 to $259.63). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-027472 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · derivative · entry 8 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $258.15 | $25,815.00 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $256.63 | $128,315.00 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,938 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $256.63 (range $256.35 to $256.96). Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 680 | $255.44 | $173,699.20 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,438 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $255.44 (range $255.03 to $255.97). Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $254.20 | $101,680.00 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,118 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $254.20 (range $253.60 to $254.55). Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $252.70 | $75,810.00 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,518 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $252.70 (range $252.48 to $252.96). Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 145 | $251.38 | $36,450.10 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,818 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $251.38 (range $251.37 to $251.38). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-20-026529 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 480 | $238.30 | $114,384.00 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $238.30 (range $238.16 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 320 | $236.26 | $75,603.20 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,318 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $236.26 (range $235.72 to $236.80). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 640 | $234.77 | $150,252.80 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,638 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.77 (range $234.51 to $235.46). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 320 | $232.89 | $74,524.80 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,278 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.89 (range $232.73 to $233.05). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 330 | $231.62 | $76,434.60 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,598 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.62 (range $231.12 to $232.06). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 938 | $230.07 | $215,805.66 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,928 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $230.07 (range $229.75 to $230.57). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.